AstraZeneca PLC (AZN)
| Previous Close | 76.41 |
| Open | 76.26 |
| Bid | 76.10 x 1100 |
| Ask | 76.20 x 1100 |
| Day's Range | 75.85 - 76.41 |
| 52 Week Range | 60.47 - 76.80 |
| Volume | |
| Avg. Volume | 6,526,681 |
| Market Cap | 236.099B |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | 37.70 |
| EPS (TTM) | 2.02 |
| Earnings Date | Jul 25, 2024 |
| Forward Dividend & Yield | 1.45 (1.90%) |
| Ex-Dividend Date | Feb 22, 2024 |
| 1y Target Est | 81.91 |
Business WireCALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
WILMINGTON, Del., May 02, 2024--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL).
Business WireAstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
WILMINGTON, Del., May 01, 2024--AstraZeneca will showcase new clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoracic Society (ATS) International Conference, in San Diego, CA from May 17 - 22, 2024. The company will present 59 abstracts, including 12 late-breaking posters, with a focus on unmet needs in chronic obstructive pulmonary disease (COPD), severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA), as
Insider MonkeyAstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript
AstraZeneca PLC (NASDAQ:AZN) Q1 2024 Earnings Call Transcript April 25, 2024 AstraZeneca PLC misses on earnings expectations. Reported EPS is $1.03 EPS, expectations were $1.22. AstraZeneca PLC isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning to those joining […]
